Moderna Inc
MRNA26.670USD
-0.680-2.49%
Cierre 06/13, 16:00（ET）Cotizaciones retrasadas 15 min
10.32BCap. mercado
PérdidaP/E TTM
Más Datos de Moderna Inc Compañía
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Información de la empresa
Símbolo de cotizaciónMRNA
Nombre de la empresaModerna Inc
Fecha de salida a bolsaDec 07, 2018
Fundada en2016
Director ejecutivoMr. Stephane Bancel
Número de empleados5800
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 07
Dirección325 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono16177146500
Sitio Webhttps://www.modernatx.com/
Símbolo de cotizaciónMRNA
Fecha de salida a bolsaDec 07, 2018
Fundada en2016
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Dr. Noubar B. Afeyan, Ph.D.
Dr. Noubar B. Afeyan, Ph.D.
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
+0.09%
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
26.89K
+2.24%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
16.19K
+3.64%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
3.08K
+46.51%
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.78B
57.41%
Rest of the World
853.00M
27.44%
Europe
598.00M
19.23%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
10.41%
Baillie Gifford & Co.
6.45%
Fidelity Management & Research Company LLC
5.39%
BlackRock Institutional Trust Company, N.A.
4.62%
State Street Global Advisors (US)
4.60%
Other
68.54%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
30.69%
Investment Advisor/Hedge Fund
25.30%
Hedge Fund
7.51%
Corporation
4.68%
Research Firm
4.38%
Individual Investor
2.56%
Bank and Trust
2.36%
Pension Fund
1.27%
Venture Capital
1.21%
Other
20.04%
Participación institucional
Actualizado: lun., 20 de ene
Actualizado: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
2090
308.33M
79.76%
-16.50M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
2022Q4
2442
300.08M
77.99%
-2.96M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
40.18M
10.39%
+101.25K
+0.25%
Dec 31, 2024
Baillie Gifford & Co.
38.89M
10.06%
-3.57M
-8.40%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.38M
4.75%
+1.28M
+7.51%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
18.04M
4.67%
+471.49K
+2.68%
Dec 31, 2024
State Street Global Advisors (US)
17.58M
4.55%
+730.02K
+4.33%
Dec 31, 2024
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Geode Capital Management, L.L.C.
7.24M
1.87%
+171.77K
+2.43%
Dec 31, 2024
Theleme Partners LLP
7.31M
1.89%
+80.00K
+1.11%
Dec 31, 2024
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Global X Genomics & Biotechnology ETF
3.72%
Langar Global HealthTech ETF
3.53%
First Trust NYSE Arca Biotechnology Index Fund
3.1%
iShares Genomics Immunology and Healthcare ETF
2.86%
VanEck Biotech ETF
2.08%
SPDR S&P Biotech ETF
1.84%
WisdomTree BioRevolution Fund
1.64%
Federated Hermes MDT Large Cap Value ETF
1.43%
Invesco S&P 500 Equal Weight Health Care ETF
1.28%
ROBO Global Healthcare Technology & Innovation ETF
1.27%
Ver más
Global X Genomics & Biotechnology ETF
Proporción3.72%
Langar Global HealthTech ETF
Proporción3.53%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.1%
iShares Genomics Immunology and Healthcare ETF
Proporción2.86%
VanEck Biotech ETF
Proporción2.08%
SPDR S&P Biotech ETF
Proporción1.84%
WisdomTree BioRevolution Fund
Proporción1.64%
Federated Hermes MDT Large Cap Value ETF
Proporción1.43%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.28%
ROBO Global Healthcare Technology & Innovation ETF
Proporción1.27%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
